Lu SL, et al. - Esophageal squamous cell carcinoma (ESCC) patients with pathological complete response (pCR) after neoadjuvant concurrent chemoradiotherapy (CCRT) with or without preceding induction chemotherapy (IC) followed by esophagectomy were compared in terms of locations of recurrences and survival outcomes. They identified 94 (34.1%) patients with pCR as eligible among 276 patients with locally advanced ESCC undergoing trimodality treatment during 2004–2014. Recurrences were reported in 19 patients at a median follow-up of 51.4 months (95% confidence interval; 42.9–62.1). Favorable survivals were observed in correlation to IC among ESCC patients with pCR after trimodality treatment. The findings thus suggest that pathological complete responders following trimodality therapy for esophageal squamous cell carcinoma may exhibit an improved prognosis with induction chemotherapy.